This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing the benefits of long-term use of the blockbuster therapy. In that study, which enrolled people with obesity and heart disease, Wegovy also cut the risk of developing diabetes by 73%. The company did not report absolute risk rates.
Gestational diabetes affects one in seven expecting women globally and rates of this troubling condition are rising. Gestational diabetes has long been diagnosed between weeks 24 and 28 of pregnancy.
It may be time to add Covid-19 infection to the list of possible risk factors for developing type 2 diabetes at a young age. Children with obesity were twice as likely to have new type 2 diabetes post-Covid and those who were sick enough to be hospitalized were almost three times as likely to do so. Read the rest…
ORLANDO — Twelve people with type 1 diabetes who received a therapy derived from stem cells were able to produce enough of their own insulin to maintain healthy blood glucose levels 90 days later, Vertex Pharmaceuticals said Friday.
Sanders held a hearing today on diabetes that implicated both the food and drug industries in what the American Diabetes Association estimates is a $413 billion annual cost to the health care system. WASHINGTON — Sen. Bernie Sanders (I-Vt.) has a new corporate target: the food industry.
Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population. Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%.
A diabetes medication which is thought to target the brains reward centre could be effective in reducing alcohol use in the future, a new study suggests. The findings are published ineClinicalMedicineand […] The post Diabetes medicine could help people drink less alcohol, research suggests appeared first on The Pharmacist.
Diagnosed about 20 years ago with type 2 diabetes, he was delighted to see his blood sugar levels improve dramatically about a year ago, when he started taking Ozempic.
An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.
ORLANDO — The United States is at a critical juncture in its efforts to treat chronic diseases, particularly type 2 diabetes, and now has a chance to change the dangerous trajectory it’s currently following, FDA Commissioner Robert Califf said Friday. “The U.S.
SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, an increasingly prevalent condition that can lead to serious liver damage.
In type 1 diabetes, immune fighters attack beta cells in the pancreas that produce insulin, the hormone that controls glucose levels in the blood. Tolerance is the holy grail in calming autoimmune disease, a truce in the immune system’s faulty battle against the body’s own fabric. Read the rest…
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.
Amgen said Tuesday that that its drug, MariTide , led to an average of roughly 20% weight loss over a year in the Phase 2 study in participants who had obesity or who were overweight without type 2 diabetes. The company added that weight loss had not plateaued at that point, suggesting that there was potential for more weight loss.
It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1
LONDON — Clinical trials have shown that lifestyle programs — which include diet, exercise, and behavioral coaching — can help people in danger of developing type 2 diabetes from tipping into a diagnosis of the condition. A study published Wednesday backs up the idea that they can. Read the rest…
Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease.
The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. As a result, they don’t reduce health care spending — they drive it up.
LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.
The advent of the first generic GLP-1 drugs could help Medicare negotiate a lower price for the highly sought after diabetes and obesity medication semaglutide , according to experts familiar with the price-negotiation program and STAT’s review of documents from the first round of negotiations.
A diabetes diagnosis was not what Jason had in mind when he set out on a cross-country road trip with his family in the fall of 2021. He went to get checked out at the Palo Alto Medical Foundation, and on a Thursday night in November, the blood test results popped up in his patient portal: He had type 2 diabetes.
On December 13, 2024, Lupin, a global pharmaceutical company, announced the acquisition of anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim International GmbH. The move is aimed at strengthening Lupins diabetes portfolio in India. In addition, 25 million people are pre-diabetic.
GSBR-1290, taken once daily, belongs to the booming class of GLP-1 drugs that increase insulin production to lower blood sugar in people with diabetes and make people feel full after eating, leading to dramatic weight loss in people with obesity. discontinuation rate that could prove to be an advantage if confirmed in larger studies.
In Stockton, California, almost 60% of the city’s 320,000 residents are prediabetic or living with diabetes. Shane Bailey, a 72-year-old longtime resident and U.S. Coast Guard veteran, is one of them.
LAS VEGAS – Nick Jonas is a global superstar behind electrifying earworms like “Jealous,” “Chains,” and “Sucker,” one-third of the illustrious band The Jonas Brothers — and also a person who lives with type 1 diabetes.
Nectar Life Care has launched a new range of anti-diabetic formulations, including Dapagliflozin under the brand name DAPNEC. India has a rising demand for diabetes management solutions, with the country often referred to as the Diabetes Capital of the World. The company reported INR 6.4
Treating patients with type II diabetes often requires an array of medications to control blood sugar and manage various comorbidities. In this article, we outline the top 10 drug […] The post Drug Interactions In Diabetes Care – Our Top 10 appeared first on Med Ed 101.
The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in 2023 to $9.9 per cent from $2.2
But in a tweet yesterday, the upstart announced that it is selling the Invokana and Invokamet diabetes drugs from Janssen, a unit at Johnson & Johnson. Until now, the company has focused on selling generic versions of brand-name medicines.
The approach involves the “prescription” of healthy food to patients who are food insecure and suffering from uncontrolled type 2 diabetes (an HbA1c > 8). They could also participate in diabetes self-management training and cooking classes.
In early October, the FDA pulled Eli Lilly’s tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — off its drug shortage list after nearly two years.
Global pharma major Lupin (Lupin) announced the re-launch of Humrahi at the Research Society for the Study of Diabetes in India (RSSDI) conference in New Delhi. Humrahi is now enhanced with comprehensive support for both diabetes and heart health.
Can Eli Lilly’s blockbuster obesity medicine lower the risk of diabetes? What does the hiring of a well-known industry dealmaker mean for the future of BioMarin Pharmaceuticals? And will Recursion Pharma, the AI drug developer, live up to all the hype? ” Read the rest…
These included diabetes, high blood pressure, fungal infections, asthma, anxiety, and rheumatoid arthritis. The state officials maintained that, as a result of the conspiracies, consumers paid more for the generic drugs than they would have otherwise if the U.S. marketplace had functioned competitively.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
More than a decade ago, Ken Mandl was on a call with a pharmaceutical company and the leader of a social network for people with diabetes. The drug maker was hoping to use the platform to encourage its members to get a certain lab test. The test could determine a patient’s need for a helpful drug.
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is another notable stumble for the company after its third-quarter earnings report disappointed. billion in revenue, less than the $13.9
Akums Drugs and Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a combination therapy for the management of type 2 diabetes. Approved by the Drugs Controller General of India (DCGI), this formulation is designed to address challenges associated with conventional diabetes treatments.
Although there is a caveat: This particular metric was based on a subset of just three drugs that were deemed to be fairly priced based on a cost-effectiveness assessment — the Mounjaro type 2 diabetes treatment, and the Wegovy and Qsymia obesity drugs. Continue to STAT+ to read the full story…
Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes, an analysis of medical records found, supporting the case for further research of the blockbuster GLP-1 drug in neurodegenerative diseases.
Medtronic is no longer buying EOFlow, a Korean maker of wearable insulin pumps. The news comes three months after Insulet, EOFlow’s rival, filed a lawsuit accusing the company of stealing trade secrets. In a filing with the Securities and Exchange Commission late Wednesday, Medtronic announced its cancellation of the deal.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content